HER2 metastatic breast cancer

The European Commission ( EC ) has granted marketing authorization for Tukysa ( Tucatinib ) in combination with Trastuzumab and...


The Food and Drug Administration ( FDA ) has approved a new fixed-dose combination of Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf ( Phesgo...


In MONARCH 2 ( M2 ), Abemaciclib ( Verzenios ), an oral selective cyclin dependent kinase 4 & 6 inhibitor,...


The CDK4/6 inhibitor Palbociclib ( Ibrance ) in combination with Letrozole ( Femara ) has become a standard first-line treatment...


Genome-wide transcriptional analysis has identified a unique subset of androgen receptor (AR)+, estrogen receptor ( ER ) / progesterone receptor...


Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


The European Commission has approved Tecentriq ( Atezolizumab ) plus chemotherapy ( Abraxane [ Paclitaxel protein-bound particles for injectable suspension...


The FDA ( U.S. Food and Drug Administration ) has warned that Ibrance ( Palbociclib ), Kisqali ( Ribociclib ),...


The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...


The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate...


The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...


HER2 targeted therapies have substantially improved the prognosis of patients with breast cancer however they can be associated with cardiac...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met...


The FDA ( US Food and Drug Administration ) has approved Kisqali ( Ribociclib ) for women with hormone-receptor positive,...


The main aim of adjuvant therapy, which is given after an apparently successful primary cancer treatment, is to reduce the...


Taxanes are a mainstay in the treatment of metastatic breast cancer ( mBC ). Combination chemotherapy, including Platinum-taxens doublets, can...


Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...


Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy...